Cutaneous manifestation is a common presentation of LCH and is usually a leading clue for the disease diagnosis. Having cutaneous lesions did not show a significantly early age onset at diagnosis compared to those without skin lesions, P value = 0.71. In the present study, cutaneous findings were found as 77.7%. Seborrheic dermatitis-like lesions were the most common cutaneous type (42.8%), followed by papules/nodules/masses (28.5%), petechiae/hemorrhagic lesions (17.8%), and eczematous lesions (10.7%). Time to diagnosis of LCH presented with seborrheic dermatitis-like lesions was significantly longer than other cutaneous presentations, P value = 0.0011.
Conclusion: Patients with LCH who had the manifestations of seborrheic dermatitis-like lesions can have diagnosis delayed due to the difficulty in distinguishing these lesions from normal seborrheic dermatitis lesions. Petechiae/hemorrhagic cutaneous signs in addition to the normal seborrheic dermatitis is the clue for early detection of the disease. To improve early detection of LCH, general pediatricians should be alerted to be aware of these skin symptoms, and if they persist, a dermatologist, pediatric if available, should be immediately consulted.
What is Known?
• Cutaneous manifestation is a common presentation of LCH and is usually a leading clue for the disease diagnosis.
What is New?
• Patients with LCH who have the manifestations of seborrheic dermatitis-like lesions can have a delayed diagnosis due to the difficulty in distinguishing normal from seborrheic dermatitis lesions.
• Petechiae/hemorrhagic cutaneous signs in addition to the normal seborrheic dermatitis are the clue to the early disease detection.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
- LCH :
Langerhans cell histiocytosis
- S-S LCH :
Single-system Langerhans cell histiocytosis
- M-S LCH :
Multisystem Langerhans cell histiocytosis
Techasatian L, Waraasawapati S (2017) Multiple yellow-red papules on the head and neck in a 3-month-old boy. Pediatr Int Off J Jpn Pediatr Soc 59(1):118–119
Mandel VD, Ferrari C, Cesinaro AM, Pellacani G, Del Forno C (2014) Congenital “self-healing” Langerhans cell histiocytosis (Hashimoto-Pritzker disease): a report of two cases with the same cutaneous manifestations but different clinical course. J Dermatol 41(12):1098–1101
Wollina U, Langner D, Hansel G, Schönlebe J (2016) Cutaneous Langerhans cell histiocytosis: the spectrum of a rare cutaneous neoplasia. Wien Med Wochenschr 1946:5
Ng SS-Y, Koh MJ-A, Tay Y-K (2013) Cutaneous Langerhans cell histiocytosis: study of Asian children shows good overall prognosis. Acta Paediatr Oslo Nor 1992 102(11):e514–e518
Morren M-A, Vanden Broecke K, Vangeebergen L, Sillevis-Smitt JH, Van Den Berghe P, Hauben E et al (2016) Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr Blood Cancer 63(3):486–492
Minkov M, Prosch H, Steiner M, Grois N, Pötschger U, Kaatsch P et al (2005) Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 45(6):802–807
Flores-Terry MA, Sanz-Trenado JL, García-Arpa M, Cortina-de la Calle MP (2018) Cutaneous Langerhans cell histiocytosis presenting in adulthood. Actas Dermosifiliogr
Allen CE, Merad M, McClain KL (2018) Langerhans-cell histiocytosis. N Engl J Med 379(9):856–868
Tran G, Huynh TN, Paller AS (2018) Langerhans cell histiocytosis: a neoplastic disorder driven by Ras-ERK pathway mutations. J Am Acad Dermatol 78(3):579–590.e4
Chong VC-L, Tan CL, Chee Y-L, De Mel S (2018) A young patient with a lytic skull lesion. J Clin Pathol 26
Zhu H, Ma Y, Sun L, Zhang R, Lv L, Wang A (2018) Langerhans cell histiocytosis with lymph node involvment presenting as erythroderma. Acta Derm Venereol
Stein SL, Paller AS, Haut PR, Mancini AJ (2001) Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series. Arch Pediatr Adolesc Med 155(7):778–783
El Fekih N, Kamoun I, Jones M, Remmeh S, Zéglaoui F, Ben Slama C et al (2013) Histiocytosis X revealed by diabetes insipidus and skin lesions. Am J Dermatopathol 35(5):606–608
Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J et al (2016) Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol 174(6):887–898
Ahuja A, Uppe A, Nair G (2018) Multisystem involvement of Langerhans cell histiocytosis. J Assoc Physicians India 66(4):75–76
Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M et al (1997) Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29(3):157–166
Behera B, Malathi M, Thappa DM, Gochhait D, Srinivas BH, Toi PC (2018) Dermoscopic features of three cases of Langerhans cell histiocytosis. Indian J Dermatol Venereol Leprol 84(6):730–735
Krooks J, Minkov M, Weatherall AG (2018) Langerhans cell histiocytosis in children: Diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol 78(6):1047–1056
Bellinato F, Maurelli M, Colato C, Balter R, Girolomoni G, Schena D (2018) BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. Br J Dermatol
Varga E, Korom I, Polyánka H, Szabó K, Széll M, Baltás E et al (2015) BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis. J Eur Acad Dermatol Venereol 29(6):1205–1211
Rizzo FM, Cives M, Simone V, Silvestris F (2014) New insights into the molecular pathogenesis of langerhans cell histiocytosis. Oncologist 19(2):151–163
Chan MMH, Tan DJA, Koh MJ-A, Tan LS (2018) Blistering Langerhans cell histiocytosis. Lancet Oncol 19(9):e500
Dodd E, Hook K (2016) Topical Imiquimod for the treatment of childhood cutaneous Langerhans cell histiocytosis. Pediatr Dermatol 33(3):e184–e185
We would like to acknowledge Prof. James Arthur Will, for editing the manuscript via publication clinic KKU, Thailand.
Ethical approval and informed consent
The study was approved by the institutional review board of Faculty of Medicine, Khon Kaen University, Thailand (IRB no. #HE591399), before enrolling any participants.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Communicated by Peter de Winter
About this article
Cite this article
Poompuen, S., Chaiyarit, J. & Techasatian, L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr 178, 771–776 (2019). https://doi.org/10.1007/s00431-019-03356-1
- Langerhans cell histiocytosis
- Seborrheic dermatitis
- Hemorrhagic lesions